Penetration of linezolid and tedizolid in cerebrospinal fluid of mouse and impact of blood–brain barrier disruption [PDF]
Clinical and Translational SciencePenetration of antimicrobial treatments into the cerebrospinal fluid is essential to successfully treat infections of the central nervous system. This penetration is hindered by different barriers, including the blood–brain barrier, which is the most ...
Marin Lahouati +5 more
doaj +3 more sources
Pharmacodynamic evidence for tedizolid use in Mycobacterium avium lung disease [PDF]
IJTLD OpenOBJECTIVE: On guideline-based therapy for Mycobacterium avium complex (MAC) lung disease (LD), ∼50%–60% of patients suffer recalcitrant disease. Tedizolid is a promising agent based on the intracellular hollow fibre model of MAC-LD (HFS-MAC) using the ...
D. Deshpande, S. Srivastava, T. Gumbo
doaj +2 more sources
Current Status and Perspectives of Antibacterial Agents Belonging to 2-Oxazolidinones [PDF]
PharmaceuticalsIn the last three decades, 2-oxazolidinones have emerged as an important class of inhibitors of bacterial protein synthesis, effective in the treatment of multidrug-resistant (MDR) bacterial infections. From a public health perspective, the importance of
Jessica Ceramella +9 more
doaj +2 more sources
Tedizolid Phosphate: a Next-Generation Oxazolidinone [PDF]
Infectious Diseases and Therapy, 2015 Treatment of multidrug-resistant Gram-positive infections continues to challenge clinicians as the emergence of new resistance mechanisms outpaces introduction of novel antimicrobial agents. Tedizolid phosphate is a next-generation oxazolidinone with activity against both methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus
Jeffrey M Rybak
exaly +3 more sources
LC-MS/MS Method for Simultaneous Quantification of Three Oxazolidinone Antimicrobials in Human Plasma: Application to Therapeutic Drug Monitoring [PDF]
Drug Design, Development and TherapyNa Zhang,* Nan Bai,* Ying Wang, Beibei Liang, Yun Cai Center of Medicine Clinical Research, Department of Pharmacy, Medical Supplies Center, PLA General Hospital, Beijing, 100853, People’s Republic of China*These authors ...
Zhang N, Bai N, Wang Y, Liang B, Cai Y
doaj +2 more sources
Single‐ and Multiple‐Dose Pharmacokinetics and Absolute Bioavailability of Tedizolid [PDF]
Pharmacotherapy, 2014 Objectives Tedizolid phosphate is a novel antibacterial under investigation for the treatment of gram‐positive infections. This study was conducted to assess the pharmacokinetics, safety, and tolerability of intravenous tedizolid phosphate as well as the oral bioavailability of tedizolid phosphate.
Flanagan, Shawn +4 more
exaly +3 more sources
In vitro Susceptibility of Nontuberculous Mycobacteria to Tedizolid
Infection and Drug Resistance, 2022 Huiyun Zhang,1 Wenya Hua,1 Siran Lin,1 Yu Zhang,1 Xinchang Chen,1 Shiyong Wang,1 Jiazhen Chen,1 Wenhong Zhang1– 3 1Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center
Zhang H +7 more
doaj +3 more sources
Tedizolid for the Management of Human Infections: In Vitro Characteristics [PDF]
Clinical Infectious Diseases, 2014 The emerging antibiotic resistance of Gram-positive pathogens represents a significant challenge to the management of human infections. The novel oxazolidinone tedizolid demonstrates antimicrobial activity across a broad range of Gram-positive pathogens and greater potency than linezolid against wild-type and drug-resistant pathogens, including ...
Karen Joy Shaw, Gary E Zurenko
exaly +3 more sources
Linezolid and tedizolid adverse effects: a review on serotonin syndrome, myelosuppression, neuropathies, and lactic acidosis [PDF]
Antimicrobial Stewardship & Healthcare EpidemiologyOxazolidinone antibiotics—linezolid and tedizolid—are often used to treat multidrug-resistant infections. They are highly bioavailable and ideal for transition to enteral therapy when appropriate.
Adam Greenfield +4 more
doaj +2 more sources
Study on the Efficacy and Safety of Tedizolid in Japanese Patients. [PDF]
Antibiotics (Basel)Background/Objective: Tedizolid (TZD), an oxazolidinone, causes fewer adverse events than linezolid (LZD). However, studies on the long-term efficacy and safety of TZD, particularly in patients with hematological malignancies (HMs), remain limited. This study aimed to evaluate the safety of long-term TZD use in Japanese patients, including those with ...
Ishikawa K, Tsuda Y, Mori N.
europepmc +4 more sources